SARS-COV2 main protease inhibitors
US12091420B2 · kind B2 · utility
1Cited by
6References
28Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 3, 2023 |
| Grant date | Sep 17, 2024 |
| Priority date | — |
| Expiry date | Oct 3, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.